Survey of management of solitary thyroid nodules in Germany

NuklearMedizin

Volumn 47, Issue 3, 2008, Pages 87-96

  Dietlein, Markus ^a   Wegscheider, K ^b   Vaupel, R ^c   Schmidt, M ^a   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Calcitonin; Iodine; Levo thyroxine; Primary care; Questionnaire; Radioiodine therapy; Thyroid nodule

Indexed keywords

CALCITONIN; IODINE; LEVOTHYROXINE; THYROTROPIN;

ARTICLE; ASPIRATION BIOPSY; ECHOGRAPHY; GERMANY; HEALTH SURVEY; QUESTIONNAIRE; SCINTIGRAPHY; THYROID NODULE;

FAMILY PRACTICE; GERMANY; HUMANS; NUCLEAR MEDICINE; QUESTIONNAIRES; REFERENCE VALUES; SPECIALTIES, MEDICAL; THYROID NODULE; THYROTROPIN;

EID: 45849139688     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0136     Document Type: Article

References (57)

1. Andermann P, Schlögl S, Mäder U et al. Intra- and interobserver variability of thyroid volume measurements in healthy adults by 2D versus 3D ultrasound. Nuklearmedizin 2007; 46: 1-7.
2. Baldini M, Gallazzi M, Orsatti A et al. Treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size. J Intern Med 2002; 251: 407-414.
3. Becker D, Bair HJ, Becker W et al. Thyroid autonomy with color-coded image-directed Doppler sonography: internal hypervascularization for the recognition of autonomous adenomas. J Clin Ultrasound 1997; 25: 63-69.
4. Bennedbaek FN, Perrild H, Hegedüs L. Diagnosis and treatment of solitary thyroid nodule. Results of a European survey. Clin Endocrinol (Oxf) 1999; 50: 357-363.
5. Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule. Results of a North American survey. J Clin Endocrinol Metab 2000; 85: 2493-2498.
6. Berghout A, Wiersinga WM, Smits NJ et al. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic non-toxic goiter. Am J Med 1990; 89: 602-608.
7. Bonnema SJ, Bennedbæk FN, Wiersinga WM et al. Management of the nontoxic multinodular goiter: a European questionnaire study. Clin Endocrinol (Oxf) 2000; 53: 5-12.
8. Bonnema SJ, Bennedbæk FN, Ladenson PW et al. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002; 87: 112-117.
9. Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002; 87: 4154-4159.
10. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1-33.
11. Diehl LA, Garcia V, Bonnema SJ et al. Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey. J Clin Endocrinol Metab 2005; 90: 117-123.
12. Dietlein M, Moka D, Schmidt M et al. Prevention, screening and therapy of thyroid diseases and their cost-effectiveness. Nuklearmedizin 2003; 42: 181-189.
13. Dietlein M, Dressler J, Grünwald F et al. Guideline for in vivo and in vitro procedures for thyroid diseases (version 2). Nuklearmedizin 2003; 42: 109-115.
14. Dietlein M, Dressler J, Grünwald F et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 2007; 46: 220-223.
15. Dietlein M, Kobe C, Schmidt M et al. The incidentaloma of the thyroid: over- or underuse of diagnostic procedures for an epidemiologic finding? Nuklearmedizin 2005; 44: 213-224.
16. Dietlein M, Dederichs B, Kobe C et al. Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 2006; 45: 21-34.
17. Dietlein M, Wegscheider K, Vaupel R et al. Management of multinodular goiter in Germany. Do the approaches of thyroid specialists and primary care practitioners differ? (Papillon 2005) Nuklearmedizin 2007; 41: 65-75.
18. Dietlein M, Moka D, Reinholz U et al. Administration of additional inactive iodide during radioiodine therapy for Graves' disease. Who might benefit? Nuklearmedizin 2007; 46: 77-84.
19. Dietlein M, Wieler H, Schmidt M et al. Routine measurement of serum calcitonin in patients with nodular thyroid disorders? Nuklearmedizin 2008; 47: 65-72.
20. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163-168.
21. From G, Mellemgaard A, Knudsen N et al. Review of thyroid cancer cases among patients with previous benign thyroid disorders. Thyroid 2000; 10: 697-700.
22. Führer D, Mügge C, Paschke R. Questionnaire on management of nodular thyroid disease (Annual Meeting of the Thyroid Section of the German Society of Endocrinology 2003). Exp Clin Endocrinol Diabetes 2005; 113: 152-159.
23. Gharib H, James EM, Charboneau JW et al. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study. N Engl J Med 1987; 317: 70-75.
24. 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s. Nuklearmedizin 2006; 45: 122-125.
25. Gotthardt M, Rubner C, Bauhofer A et al. What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy? Nuklearmedizin 2006; 45: 206-212.
26. Grussendorf M, Vaupel R, Reiners C et al, the LISA-study group. The LISA trial - a randomized, double-blind, placebo-controlled four-arm study of 1,000 patients with nodular goiter in Germany. Study design and first results of feasibility. Med Klinik 2005; 100: 542-546.
27. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of non-palpable thyroid nodules. Thyroid 1998; 8: 989-995.
28. Hampel R. Aktuelle Iodversorgung in Deutschland. In: Dietlein M, Schicha H (Hrsg). Schilddrüse 2003 - Zufallsbefund Schilddrüsenknoten - Latente Schilddrüsenfunktionsstörungen. Berlin: de Gruyter, 2004: 52-61.
29. Kahaly GJ, Dietlein M. Cost estimation of thyroid disorders in Germany. Thyroid 2002; 12: 909-914.
30. Karges W, Dralle H, Raue F et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58.
31. La Rosa G, Lupo L, Giuffrida D et al. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid. Ann Intern Med 1995; 122: 1-8.
32. Larijani B, Pajouhi M, Bastanhagh M et al. Evaluation of suppressive therapy for cold thyroid nodules with levothyroxine: double blind placebo-controlled clinical trial. Endocr Pract 1999; 5: 251-256.
33. Leenhardt L, Hejblum G, Franc B et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84: 24-28.
34. Liel Y, Ariad S, Barchana M. Long-term follow-up of patients with initially benign thyroid fine-needle aspirations. Thyroid 2001; 11: 775-778.
35. Luster M, Führer D, Engelhardt C et al. Prävalenz von szintigraphisch heißen, kalten und indifferenten Schilddrüsenknoten bei Patienten mit bekanntem solitärem Herdbefund. Nuklearmedizin 2005; 44: A6-A7.
36. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553-559.
37. Mellemgaard A, From G, Jorgensen T et al. Cancer risk in individuals with benign thyroid disorders. Thyroid 1998; 8: 751-754.
38. Nam-Goong IS, Kim HY, Gong G et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathologic findings. Clin Endocrinol 2004; 60: 21-28.
39. Pacini F, Schlumberger M, Dralle H et al., the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
40. Papini E, Bacci V, Panunzi C et al. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf) 1993; 38: 507-513.
41. Papini E, Petruci L, Guglielmi R et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 1998; 83: 780-783.
42. Papini E, Guglielmi R, Bianchini A et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87: 1941-1946.
43. Parle JV, Maisonneuve P, Sheppard MC et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358: 861-865.
44. Quadbeck B, Pruellage J, Roggenbuck U. Longterm follow-up of thyroid nodule growth. Exp Clin Endocrinol Diabetes 2002; 110: 348-354.
45. Raber W, Kmen E, Kaserer K et al. The cold thyroid nodule: 20 year experience with 2071 patients and diagnostic limitations of fine needle aspiration biopsy. Wien Klin Wochenschr 1991; 109: 116-122.
46. Raber W, Kaserer K, Niederle B et al. Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. Thyroid 2000; 10: 709-712.
47. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma. A retrospective study in 37,895 patients. Cancer (Cancer Cytopathol) 2000; 90: 357-363.
48. Reiners C, Wegscheider K, Schicha H et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unchosen employees. Thyroid 2004; 14: 926-932.
49. Schumm-Draeger PM, Vaupel R, Wegscheider K. Insufficient adherence to recommendations on medical treatment of patients with nodular or diffuse goiter by German practitioners. Med Welt 2006; 57: 224-227.
50. Tagay S, Herpertz S, Langkafel M et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol 2005; 153: 755-763.
51. Verschreibungsindex für Pharmazeutika. IMS VIP® 2005. www.imshealth.de.
52. Völzke H, Ludemann J, Robinson DM et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803-810.
53. Vogt H, Wengenmair H, Kopp J et al. Radioiodine therapy for combined disseminated and nodular thyroid autonomy. Nuklearmedizin 2006; 45: 101-104.
54. Watt T, Groenvold M, Rasmussen AK et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol 2006; 154: 501-510.
55. Wémeau J-L, Caron P, Schvartz C et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 2002; 87: 4928-4934.
56. Wesche MF, Tiel-Van Buul MM, Lips P et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86: 998-1005.
57. Zelmanovitz F, Genro S, Gross J. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 83: 3881-3885.